Loading…

COVID-19 Vaccines and Ivermectin with MedCram and Dr. Roger Seheult

RP

Rhonda Patrick2h 24m · 2021-09-17

Support Rate

57%

113 of 197 claims supported

Support rate

113 of 197 claims supported

113 supported84 partial / not

Claims from this content

135

Well SupportedmRNA vaccines cannot alter DNA because mRNA does not enter the cell nucleus.Partially SupportedCurrent U.S. vaccines use the pre-fusion spike protein, making antibody-dependent enhancement (ADE) unlikely.Partially SupportedThe risk of myocarditis from COVID-19 vaccines in young people may be exceeded by the risk of myocarditis from natural COVID-19 infection.Partially SupportedReported deaths from COVID-19 vaccines in VAERS are lower than deaths from COVID-19 itself.Well SupportedViruses that do not kill their host are more evolutionarily advantageous than those that do.

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

Partially Supported

Antibody-dependent enhancement occurs when antibodies bind to a pathogen but do not neutralize it, potentially activating immune cells to cause more damage.

Partially SupportedThe primary selective pressure on viruses is to become more transmissible.

Not SupportedInterpreting raw VAERS data to conclude vaccines cause deaths without proper statistical analysis is not supported by the data.

Partially SupportedVaccines remain effective in preventing hospitalization and severe disease despite reduced transmission of the Delta variant.

Partially SupportedmRNA technology is being explored as a therapeutic for genetic disorders like muscular dystrophy.

Partially SupportedVaccines may allow viruses to mutate into more virulent forms by enabling continued transmission.

Partially SupportedThe SARS-CoV-2 virus has approximately 26 spike proteins on its surface that bind to the ACE2 receptor on human cells.

Partially SupportedBased on the average U.S. death rate and COVID-19 vaccinations, approximately 421,000 deaths would be expected by chance over an average vaccination period of 3.5 months, significantly higher than reported deaths.

Partially SupportedThe lipid nanoparticle encapsulating mRNA in vaccines has a very short lifespan, lasting only long enough to protect the mRNA from degradation.

Partially SupportedCOVID-19 infection is associated with a significant loss of gray matter in several brain regions.

Partially SupportedViral infections hijack cellular ribosomes to produce viral proteins, a process analogous to how mrna vaccines function.

Partially SupportedSome studies in nonhuman primates given SARS-CoV-1 vaccines showed protection without antibody-dependent enhancement.

Well SupportedAntibodies are crucial for neutralizing viruses outside of cells, preventing infection.

Partially SupportedLower antibody titers in vaccinated individuals are associated with a higher likelihood of breakthrough COVID-19 infections.

Not SupportedSpike proteins in SARS-CoV-2 and United States vaccines are structurally different due to proline insertions, making in vitro or animal study findings on SARS-CoV-2 spike protein not directly applicable to vaccine spike protein.

Partially SupportedPhase three trials for COVID-19 vaccines showed no statistically significant difference in pregnancies and miscarriages between vaccinated and control groups.

Partially SupportedA study in the 'New England Journal of Medicine' found no statistically significant difference in pregnancy loss, spontaneous abortions, stillbirth, neonatal outcomes, preterm births, small size for gestational age, congenital abnormalities, or neonatal death between pregnant individuals vaccinated with mRNA COVID-19 vaccines and the general population.

Partially SupportedCOVID-19 can cause complications and long-term effects that are not fully understood.

Partially SupportedThe Delta variant of COVID-19 is causing hospitalization rates in younger populations (e.g., 20s and 30s) to approach those of the elderly, which was not observed with earlier variants.

Partially SupportedCOVID-19 survivors can develop blood clots requiring treatment with blood thinners.

Partially SupportedCOVID-19 vaccines stabilize the spike protein in a pre-fusion conformation using proline amino acid insertions.

Partially SupportedThe Moderna mRNA vaccine showed approximately 77% efficacy against SARS-CoV-2 infection with the Delta variant, about twice that of the Pfizer vaccine.

Partially SupportedThe free plasma concentration of ivermectin achievable in humans is about 250 times lower than the concentration required in vitro to reduce SARS-CoV-2 viral replication.

Partially SupportedConcerns that mRNA vaccines distribute widely and cause spike protein-related damage are based on rodent studies using high concentrations.

Partially SupportedIn vitro studies showed that ivermectin at a concentration of 5 micromolar can reduce SARS-CoV-2 virus reproduction by approximately 5,000-fold.

Partially SupportedThe VAERS reporting system can be used to generate hypotheses but not to test them directly.

Partially SupportedT cells may be able to anticipate and mutate along with viral mutations.

Partially SupportedThe effectiveness of COVID-19 vaccines against infection has decreased with the Delta variant.

Partially SupportedThe average U.S. death rate is approximately 870 deaths per 100,000 population per year.

Partially SupportedRandomized controlled trials are needed to determine if ivermectin should be used in the US population.

Partially SupportedA meta-analysis on ivermectin included a randomized controlled trial that was later retracted due to suspected fraud.

Partially SupportedPeak viral load in breakthrough COVID-19 infections can be similar between vaccinated and unvaccinated individuals.

Partially SupportedPost-fusion antibodies are a major factor in antibody-dependent enhancement (ADE).

Partially SupportedVaccinated individuals with COVID-19 clear the virus faster than unvaccinated individuals.

Partially SupportedPrior SARS-CoV-2 infection or COVID-19 vaccination did not affect embryo implantation.

Partially SupportedA small study on men found no effect of COVID-19 vaccines on sperm parameters such as motility.

Partially SupportedCOVID-19 vaccines reduce transmission of the virus.

Partially SupportedCOVID-19 vaccines have no significant effect on fertility.

Partially SupportedmRNA vaccines are a protein-making technology that do not alter DNA.

Partially SupportedUpon binding to the ACE2 receptor, the SARS-CoV-2 spike protein undergoes a conformational change that facilitates fusion with the cell membrane and viral entry.

Partially SupportedThe hospitalization rate for COVID-19 in young people is approximately 20-fold higher than that for the flu.

Partially SupportedViral variants such as Alpha, Beta, Gamma, and Delta predominantly emerged from unvaccinated populations.

Partially SupportedContracting SARS-CoV-2 poses a greater risk of spike protein exposure and damage compared to vaccination.

Partially SupportedA study found higher risks for acute kidney injury, arrhythmia, deep venous thrombosis, pulmonary embolism, and myocardial infarction in individuals infected with SARS-CoV-2 compared to those vaccinated with Pfizer-BioNTech.

Partially SupportedYoung males infected with the virus are up to six times more likely to develop myocarditis than those vaccinated, according to a pre-print article using US electronic health records.

Not SupportedCOVID-19 vaccines do not impact human fertility as vaccine antibodies do not cross-react with placental proteins.

Partially SupportedMedical decisions involve inherent risks, and it is not possible to avoid causing harm entirely, though the goal is to maximize benefit over harm.

Partially SupportedmRNA technology has been in development and use in humans for decades, with the first clinical trial in 2001.

Partially SupportedThe absence of a second peak in reported deaths around three to four weeks after vaccination suggests the second shot is not causing problems like myocarditis or myocardial infarction.

Partially SupportedMice given 2 micrograms of mRNA vaccine showed no significant distribution of radio-labeled tag to organs other than the liver, with clearance within 48 hours.

Partially SupportedConcerns about spike protein from mRNA or Johnson & Johnson vaccines causing widespread damage are likely unfounded.

Partially SupportedmRNA vaccines are easier to mass produce compared to traditional vaccines that require growing vaccine in animal cell types.

Partially SupportedThe pattern of reported deaths after vaccination, with a sharp decline after one or two days, is consistent with reporting biases and human psychology rather than a spike protein causing deaths.

Partially SupportedPost-acute COVID syndrome can include brain fog, racing heart, and lethargy, even in individuals with mild symptoms.

Partially SupportedHigh vaccination rates have not led to a disproportionate emergence of variants.

Partially SupportedThe number of reported deaths following vaccination is significantly lower than the expected number of deaths based on background mortality rates.

Partially SupportedViral particles shed from vaccinated individuals are less likely to infect others compared to those shed from unvaccinated individuals.

Partially SupportedFocusing on ivermectin's potential effect on viral clearance, rather than grandiose claims, may increase research interest.

Partially SupportedCOVID-19 can cause blood clots in the lungs and brain, in addition to lung inflammation.

Partially SupportedBoth severe and mild COVID-19 cases can lead to brain atrophy.

Partially SupportedPlatform trials like the Together Trial can rapidly assess the efficacy of repurposed medications.

Partially SupportedYounger people, including teenagers and those in their 20s, are disproportionately affected by long-haul COVID syndrome.

Partially SupportedSome viruses, such as HIV and certain herpes viruses, can convert back into DNA and affect a person's own DNA.

Partially SupportedThe presence of antibodies against the spike protein is expected to lead to virus clearance.

Partially SupportedReal-time PCR can detect dead viral particles, which may lead to an overestimation of infectious viral load.

Partially SupportedRepurposed medications should be studied in randomized controlled trials under specific study platforms.

Partially SupportedHuman cellular machinery and metabolic capacity impose physical constraints on viral replication, limiting peak transmissibility.

Partially SupportedHigh-quality data from countries without a high background of parasitic disease is needed to assess ivermectin's efficacy.

Partially SupportedThere are no documented cases of human vaccines causing a more virulent viral strain, although vaccine escape variants do occur.

Partially SupportedIndividuals are more likely to die from COVID-19 than from a COVID-19 vaccine across all age groups.

Partially SupportedOptimizing vitamin D levels, metabolic health, diet, weight, and sleep are crucial for health and immunity.

Not SupportedThere is no evidence that ivermectin protects against COVID-19 infection and severe disease as effectively as a vaccine.

Not SupportedUsing veterinary formulations of ivermectin is dangerous due to vastly different dosages compared to human formulations.

Not SupportedInterpreting VAERS data requires stratification and consideration of other factors.

Partially SupportedThe most significant risk difference per hundred thousand persons associated with the Pfizer-BioNTech vaccine is lymphadenopathy, which is a normal response.

Partially SupportedAnimal studies involving direct injection of recombinant or pseudovirus spike protein into hamster tracheas have shown severe lung damage and circulatory/vascular damage.

Partially SupportedTwo proline amino acids in the spike protein lock it into the pre-fusion conformation, preventing cell membrane fusion.

Partially SupportedPfizer and Moderna vaccines remained highly effective at preventing COVID-19 hospitalizations.

Partially SupportedStatistics and scientific evidence should guide medical decisions, as past individual adverse events do not necessarily predict future outcomes.

Partially SupportedCurrent COVID-19 vaccines in the United States are unlikely to cause antibody-dependent enhancement.

Partially SupportedViral resistance to vaccines develops through viral replication, a mechanism distinct from bacterial resistance to antibiotics.

Partially SupportedThe overuse of antibiotics can lead to bacterial resistance and the emergence of 'superbugs' that are not susceptible to existing antibiotics.

Partially SupportedmRNA technology is being used in clinical trials as immunotherapy for cancers, with the potential to lead to cures for solid tumors.

Partially SupportedmRNA vaccine technology has been used in humans in clinical trials since at least 2001 for influenza and heart failure.

Partially SupportedIvermectin may speed up viral clearance to a degree.

Not SupportedMeta-analyses on ivermectin may suffer from methodological issues like co-treatments and small sample sizes.

Not SupportedA study reporting spike protein detection in vaccinated individuals cannot draw conclusions due to a 25% false positivity rate and small sample size.

Not SupportedAggregating data from studies with vastly different clinical endpoints can be misleading.

Partially SupportedSolid tumors are difficult to treat with chemotherapy because they can grow far from blood vessels, leading to hypoxic conditions and resistance to treatment.

Partially SupportedInjecting mRNA technology directly into solid tumors can activate the immune system to target and kill cancer cells.

Partially SupportedAdequate sleep, vitamin D supplementation, exercise, stress reduction, fresh air, and sunlight offer significant benefits for overall health and longevity.

Partially SupportedIn Israel, unvaccinated individuals experienced more severe COVID-19 cases compared to vaccinated individuals during the Delta variant prevalence.

Partially SupportedThe risk of myocarditis and pericarditis is higher following SARS-CoV-2 infection than following vaccination with the Pfizer-BioNTech vaccine, according to Israeli data.

Partially SupportedDuring the UK's third wave (Delta variant), infections increased but deaths did not rise proportionally, indicating vaccine effectiveness in preventing mortality.

Partially SupportedCytotoxic T cell responses are more crucial than antibodies for combating viruses that have already infected cells.

Partially SupportedCOVID-19 vaccines have demonstrated effectiveness in protecting billions of people worldwide from severe disease and infection.

Partially SupportedThe accelerated timeline for COVID-19 vaccine development involved compressing standard phases, running some concurrently, but did not skip any phases (research, pre-clinical, Phase 1, 2, 3, manufacturing, approval, distribution).

Partially SupportedGiven the vast number of people vaccinated worldwide (over a billion) and in the US (over 177 million), any medication or vaccine with widespread severe adverse effects would be clearly identified by now.

Partially SupportedThe development of COVID-19 vaccines was accelerated, but the quality of the product was not compromised.

Partially SupportedThe Swiss cheese model suggests that multiple layers of protection (e.g., vaccination, masks) provide better overall protection against undesired outcomes than relying on a single measure.

Partially SupportedSome ivermectin studies consistently found a faster time to a negative PCR, potentially due to ivermectin in combination with other treatments.

Partially SupportedViral particles shed from vaccinated individuals with breakthrough COVID-19 infections may be less capable of growing in viral culture compared to those shed from unvaccinated individuals.

Partially SupportedIndividual responses to medications, vaccines, and foods can vary significantly.

Partially SupportedStatistical analysis of epidemiological studies is necessary to determine if a condition is linked to an event.

Partially SupportedIncreased vaccination rates during the 2009 H1N1 epidemic correlated with more adverse event reports, not necessarily due to vaccine safety issues.

Partially SupportedThe spike protein from mRNA vaccination is anchored to the plasma membrane and not freely circulating.

Partially SupportedThe aggregation of data from studies with small sample sizes can lead to a low certainty of a causal relationship between a treatment and a clinical endpoint.

Partially SupportedA Pfizer study showed radio-labeled lipid nanoparticles in various organs of rats given 10 times the human dose of their mRNA vaccine.

Partially SupportedIvermectin may reduce death compared to no ivermectin, but evidence certainty is low for other conclusions.

Partially SupportedNon-neutralizing antibodies can paradoxically increase the immune system's damaging potential in antibody-dependent enhancement.

Partially SupportedFluvoxamine shows a better signal than ivermectin in ongoing trials for potential anti-inflammatory and antioxidant properties.

Partially SupportedA study using pre-pandemic samples showed positive results for spike protein, suggesting a high false positivity rate in the detection method.

Partially SupportedThe Vaccine Adverse Event Reporting System (VAERS) in the US requires reporting of any hospitalization or death following vaccination by law.

Partially SupportedThe spike protein produced by mRNA vaccines peaks approximately 24 hours after injection and has a half-life of about 48 hours.

Partially SupportedA 2016 study examined adverse events after seasonal influenza vaccination in pregnant women and their infants from July 2010 to May 2016.

Partially SupportedA significant percentage of young people under 50 experiencing strokes had COVID-19.

Partially SupportedThe SARS-CoV-2 virus, including its spike protein, has been detected in human organs such as the heart, brain, kidneys, GI tract, testes, and in the circulatory system.

Partially SupportedAspirin and blood thinners treat conditions like heart attacks and atrial fibrillation but carry risks like bleeding or ulcers.

Partially SupportedMedicine inherently involves risks, and the goal is to achieve more benefit than harm, as exemplified by the use of aspirin for heart attack patients.

Partially SupportedA small study detected spike protein subunits in individuals vaccinated with Moderna mRNA, but the assay has a 25% false positivity rate.

Partially SupportedA 1960s RSV vaccine trial in infants showed an 80% hospitalization rate in vaccinated children compared to 5% in the placebo group after natural RSV exposure.

Partially SupportedIn populations with high rates of parasitic infections, dexamethasone's immunosuppression might activate parasites, making ivermectin potentially beneficial for concomitant infections.

Partially SupportedImmune cells can process radio-labeled lipid nanoparticles, leading to remnants being taken to other tissues for recycling.

Partially SupportedCOVID-19 can lead to other conditions such as pneumonia, ARDS, pulmonary embolism, or stroke, which are the actual causes of death.

Partially SupportedRepurposed therapeutics with known safety and some positive effects against SARS-CoV-2 should be studied to fight the pandemic.

Partially SupportedYoung people face a more transmissible Delta variant and potentially future variants, with a higher risk of hospitalization compared to earlier in 2021.

Partially SupportedVaccine escape immunity, where variants evade antibodies, is distinct from increased virulence.

Partially SupportedCytotoxic T cells are an important aspect of the immune system that contributes to protection against hospitalization.

Partially SupportedThe transmission phase of SARS-CoV-2 typically precedes host death, suggesting that host mortality is not the primary limiter of viral evolution.

Partially SupportedA six-fold higher antibody titer level is needed to prevent contracting SARS-CoV-2 compared to preventing hospitalization from the virus.